{"id":57916,"date":"2026-02-25T14:02:03","date_gmt":"2026-02-25T06:02:03","guid":{"rendered":"https:\/\/flcube.com\/?p=57916"},"modified":"2026-02-25T14:02:04","modified_gmt":"2026-02-25T06:02:04","slug":"henlius-licenses-serplulimab-to-abbott-for-emerging-markets-expands-anti-pd-1-global-footprint","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57916","title":{"rendered":"Henlius Licenses Serplulimab to Abbott for Emerging Markets \u2013 Expands Anti\u2011PD\u20111 Global Footprint"},"content":{"rendered":"\n<p><strong>Shanghai Henlius Biotech, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG:\u202f2696<\/a>)<\/strong> announced an <strong>exclusive license agreement<\/strong> with <strong>Abbott<\/strong> for the commercialization of <strong>serplulimab<\/strong> (trade name in Europe: <strong>Hetronifly<\/strong>), Henlius&#8217; <strong>novel anti\u2011PD\u20111 monoclonal antibody<\/strong>, across selected emerging markets. The deal covers <strong>Asia Pacific, Africa, Central Asia, Eastern Europe<\/strong>, and other developing regions, significantly expanding serplulimab&#8217;s global reach beyond existing partnerships.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Shanghai Henlius Biotech, Inc. (HKG:\u202f2696)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Abbott<\/td><\/tr><tr><td><strong>Licensed Product<\/strong><\/td><td>Serplulimab (Hetronifly in Europe) \u2013 anti\u2011PD\u20111 mAb<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Asia Pacific, Africa, Central Asia, Eastern Europe, and other emerging regions<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Exclusive commercialization<\/td><\/tr><tr><td><strong>Prior Collaborations<\/strong><\/td><td>2022 and 2024 agreements (oncology biosimilars + serplulimab in Latin America)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-serplulimab-regulatory-status\">Serplulimab Regulatory Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Approvals<\/strong><\/td><td><strong>40+ countries and regions<\/strong> (as of Dec\u202f2025)<\/td><\/tr><tr><td><strong>Key Markets Approved<\/strong><\/td><td>China, EU, UK, Switzerland, Peru, India, Southeast Asia<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Novel anti\u2011PD\u20111 monoclonal antibody<\/td><\/tr><tr><td><strong>Commercial Partners<\/strong><\/td><td>Fosun Pharma, Intas, PT Kalbe Genexine Biologics (KGbio), Abbott<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Emerging Market Access:<\/strong> Abbott&#8217;s <strong>established commercial infrastructure<\/strong> across Asia Pacific, Africa, and Eastern Europe provides Henlius with immediate market access in regions where building proprietary sales forces would be capital\u2011intensive and time\u2011consuming.<\/li>\n\n\n\n<li><strong>Partnership Continuity:<\/strong> This agreement <strong>builds on two prior collaborations<\/strong> (2022, 2024), demonstrating successful execution and deepening trust between Henlius and Abbott in oncology commercialization.<\/li>\n\n\n\n<li><strong>Global Expansion Strategy:<\/strong> Henlius continues to execute a <strong>multi\u2011partner global strategy<\/strong>, leveraging regional specialists (Fosun in China, Intas in India, KGbio in Southeast Asia, Abbott in emerging markets) rather than attempting solo global launches.<\/li>\n\n\n\n<li><strong>PD\u20111 Market Positioning:<\/strong> With <strong>40+ approvals<\/strong>, serplulimab is establishing itself as a <strong>differentiated anti\u2011PD\u20111 option<\/strong>, competing with Keytruda, Opdivo, and domestic Chinese PD\u20111 inhibitors through strategic geographic segmentation.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Emerging Market Oncology Growth<\/strong><\/td><td>High\u2011growth regions with increasing cancer burden and expanding healthcare access; PD\u20111 inhibitors represent premium therapeutic category<\/td><\/tr><tr><td><strong>Abbott&#8217;s Commercial Strength<\/strong><\/td><td>Deep primary care and specialty care presence in target regions; proven track record in oncology biosimilars and novel biologics<\/td><\/tr><tr><td><strong>Henlius Revenue Diversification<\/strong><\/td><td>Milestone and royalty income from multiple geographic partnerships reduces reliance on any single market<\/td><\/tr><tr><td><strong>Competitive Dynamics<\/strong><\/td><td>Serplulimab gains first\u2011mover advantage in select emerging markets ahead of other Chinese PD\u20111 inhibitors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch timelines, market penetration rates, and revenue projections for serplulimab in Abbott territories. Actual results may differ due to risks including reimbursement negotiations, competitive launches, and regulatory delays in specific countries.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Henlius Biotech, Inc. (HKG:\u202f2696) announced an exclusive license agreement with Abbott for the commercialization&#8230;<\/p>\n","protected":false},"author":1,"featured_media":57917,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[503,270,862,18],"class_list":["post-57916","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-abbott","tag-henlius-biotech","tag-hkg-2696","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Henlius Licenses Serplulimab to Abbott for Emerging Markets \u2013 Expands Anti\u2011PD\u20111 Global Footprint - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech, Inc. (HKG:\u202f2696) announced an exclusive license agreement with Abbott for the commercialization of serplulimab (trade name in Europe: Hetronifly), Henlius&#039; novel anti\u2011PD\u20111 monoclonal antibody, across selected emerging markets. The deal covers Asia Pacific, Africa, Central Asia, Eastern Europe, and other developing regions, significantly expanding serplulimab&#039;s global reach beyond existing partnerships.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57916\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius Licenses Serplulimab to Abbott for Emerging Markets \u2013 Expands Anti\u2011PD\u20111 Global Footprint\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech, Inc. (HKG:\u202f2696) announced an exclusive license agreement with Abbott for the commercialization of serplulimab (trade name in Europe: Hetronifly), Henlius&#039; novel anti\u2011PD\u20111 monoclonal antibody, across selected emerging markets. The deal covers Asia Pacific, Africa, Central Asia, Eastern Europe, and other developing regions, significantly expanding serplulimab&#039;s global reach beyond existing partnerships.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57916\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-25T06:02:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-25T06:02:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2503.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57916#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57916\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius Licenses Serplulimab to Abbott for Emerging Markets \u2013 Expands Anti\u2011PD\u20111 Global Footprint\",\"datePublished\":\"2026-02-25T06:02:03+00:00\",\"dateModified\":\"2026-02-25T06:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57916\"},\"wordCount\":407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57916#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2503.webp\",\"keywords\":[\"Abbott\",\"Henlius Biotech\",\"HKG: 2696\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57916#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57916\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57916\",\"name\":\"Henlius Licenses Serplulimab to Abbott for Emerging Markets \u2013 Expands Anti\u2011PD\u20111 Global Footprint - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57916#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57916#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2503.webp\",\"datePublished\":\"2026-02-25T06:02:03+00:00\",\"dateModified\":\"2026-02-25T06:02:04+00:00\",\"description\":\"Shanghai Henlius Biotech, Inc. (HKG:\u202f2696) announced an exclusive license agreement with Abbott for the commercialization of serplulimab (trade name in Europe: Hetronifly), Henlius' novel anti\u2011PD\u20111 monoclonal antibody, across selected emerging markets. The deal covers Asia Pacific, Africa, Central Asia, Eastern Europe, and other developing regions, significantly expanding serplulimab's global reach beyond existing partnerships.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57916#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57916\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57916#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2503.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2503.webp\",\"width\":1080,\"height\":608,\"caption\":\"Henlius Licenses Serplulimab to Abbott for Emerging Markets \u2013 Expands Anti\u2011PD\u20111 Global Footprint\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57916#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius Licenses Serplulimab to Abbott for Emerging Markets \u2013 Expands Anti\u2011PD\u20111 Global Footprint\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius Licenses Serplulimab to Abbott for Emerging Markets \u2013 Expands Anti\u2011PD\u20111 Global Footprint - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Henlius Biotech, Inc. (HKG:\u202f2696) announced an exclusive license agreement with Abbott for the commercialization of serplulimab (trade name in Europe: Hetronifly), Henlius' novel anti\u2011PD\u20111 monoclonal antibody, across selected emerging markets. The deal covers Asia Pacific, Africa, Central Asia, Eastern Europe, and other developing regions, significantly expanding serplulimab's global reach beyond existing partnerships.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57916","og_locale":"en_US","og_type":"article","og_title":"Henlius Licenses Serplulimab to Abbott for Emerging Markets \u2013 Expands Anti\u2011PD\u20111 Global Footprint","og_description":"Shanghai Henlius Biotech, Inc. (HKG:\u202f2696) announced an exclusive license agreement with Abbott for the commercialization of serplulimab (trade name in Europe: Hetronifly), Henlius' novel anti\u2011PD\u20111 monoclonal antibody, across selected emerging markets. The deal covers Asia Pacific, Africa, Central Asia, Eastern Europe, and other developing regions, significantly expanding serplulimab's global reach beyond existing partnerships.","og_url":"https:\/\/flcube.com\/?p=57916","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-25T06:02:03+00:00","article_modified_time":"2026-02-25T06:02:04+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2503.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57916#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57916"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius Licenses Serplulimab to Abbott for Emerging Markets \u2013 Expands Anti\u2011PD\u20111 Global Footprint","datePublished":"2026-02-25T06:02:03+00:00","dateModified":"2026-02-25T06:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57916"},"wordCount":407,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57916#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2503.webp","keywords":["Abbott","Henlius Biotech","HKG: 2696","PD-1\/L1"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57916#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57916","url":"https:\/\/flcube.com\/?p=57916","name":"Henlius Licenses Serplulimab to Abbott for Emerging Markets \u2013 Expands Anti\u2011PD\u20111 Global Footprint - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57916#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57916#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2503.webp","datePublished":"2026-02-25T06:02:03+00:00","dateModified":"2026-02-25T06:02:04+00:00","description":"Shanghai Henlius Biotech, Inc. (HKG:\u202f2696) announced an exclusive license agreement with Abbott for the commercialization of serplulimab (trade name in Europe: Hetronifly), Henlius' novel anti\u2011PD\u20111 monoclonal antibody, across selected emerging markets. The deal covers Asia Pacific, Africa, Central Asia, Eastern Europe, and other developing regions, significantly expanding serplulimab's global reach beyond existing partnerships.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57916#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57916"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57916#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2503.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2503.webp","width":1080,"height":608,"caption":"Henlius Licenses Serplulimab to Abbott for Emerging Markets \u2013 Expands Anti\u2011PD\u20111 Global Footprint"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57916#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius Licenses Serplulimab to Abbott for Emerging Markets \u2013 Expands Anti\u2011PD\u20111 Global Footprint"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2503.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57916"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57916\/revisions"}],"predecessor-version":[{"id":57918,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57916\/revisions\/57918"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57917"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}